Human Papillomavirus in Cervical Cancer and Pre-cancer in Switzerland: The CIN3+Plus Study
NCT ID: NCT02323997
Last Updated: 2019-07-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
767 participants
OBSERVATIONAL
2015-01-31
2016-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevalence of HPV Infection Using Self-sampling
NCT03474211
Multiple Human Papillomavirus Infections in the Development of CIN
NCT06862102
Use of Human Papillomavirus Persistence for Determination of Treatment Efficacy Among Women With Cervical Dysplasia
NCT00931190
Multimodality Treatments of HPV-related Lesions of the Female Genital Tract
NCT05938192
Breast Cancer-Related Approach for Increasing Cervical Cancer Screening
NCT07171658
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participant is literate in German, French, Italian or English.
* Female, aged 18 years or above.
* Histologically confirmed CIN3+ lesions, i.e. CIN3, adenocarcinoma in situ and invasive carcinoma of the cervix.
* Participant resides in the canton Zurich, Geneva, Basel, Baselland, Luzern or Ticino.
Exclusion Criteria
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Federal Office of Public Health, Switzerland
OTHER_GOV
University of Bern
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nicola Low
Role: PRINCIPAL_INVESTIGATOR
University of Bern, Institute of Social and Preventive Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Viollier AG
Allschwil, Basel-Landschaft, Switzerland
Universitätsspital Basel
Basel, , Switzerland
Viollier Weintraub SA
Geneva, , Switzerland
HUG - Hôpitaux Universitaires de Genève
Geneva, , Switzerland
Kantonsspital Baselland
Liestal, , Switzerland
Istituto cantonale di patologia
Locarno, , Switzerland
Kantonsspital Luzern
Lucerne, , Switzerland
Institute of Pathology Enge
Zurich, , Switzerland
Institut für klinische Pathologie Medica
Zurich, , Switzerland
Universitätsspital Zürich
Zurich, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Egli-Gany D, Spaar Zographos A, Diebold J, Masserey Spicher V, Frey Tirri B, Heusser R, Dillner J, Petignat P, Sahli R, Low N; CIN3+plus study group. Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study. BMC Cancer. 2019 Jan 30;19(1):111. doi: 10.1186/s12885-018-5248-y.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CIN3+plus
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.